Highlighted PresentationsPharmacologyAntiplatelet

SOLACI-SBHCI 2023 | Is very short DAPT safe in HBR patients undergoing complex PCI – Dr. Marco Valgimigli

solaci
solaci
635
0

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress.

In this case, check the presentation by Dr. Marco Valgimigli, entitled “Is very short DAPT safe in HBR patients undergoing complex PCI”

Marco-valgimigli-solaci-sbhci-2023

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
SOLACI-SBHCI 2023 | Acute pulmonary embolysmworkflow: Patient Screening & Endovascular treatment indications – Dr. João Luiz Frighetto
Next article
Moderate Aortic Stenosis: We Should Start Assessing It More Thoroughly
solaci
solaci

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

Dr. Andrés Rodríguez - 0
In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

Dr. Andrés Rodríguez - 0
This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

Dr. Andrés Rodríguez - 0
This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

Dr. Andrés Rodríguez - 0
This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Acute coronary syndromes

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current...
Dr. Andrés Rodríguez -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Dr. Juan Manuel Pérez - 0
Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

Supera vs. Eluvia at 3 Years in Severely Calcified Femoropopliteal Lesions

Dr. Juan Manuel Pérez - 0
Severe calcification remains one of the main predictors of restenosis and the need for repeat revascularization following endovascular treatment of femoropopliteal disease. In this...

Is IVUS Always Necessary for Left Main Coronary Artery PCI?

Dr. Juan Manuel Pérez - 0
Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery is a highly complex procedure because of the large amount of myocardium at...